Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elelyso in Type 3 Gaucher Disease
NCT04002830Phase 4Completed
- Start
- Nov 2020
- Primary completion
- Jul 2023
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 4 trial of taliglucerase alfa in Gaucher disease type 3. Started Nov 2020; status: completed.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT04002830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002830.